A novel coumarin-quinone derivative SV37 inhibits CDC25 phosphatases, impairs proliferation, and induces cell death

Molecular Carcinogenesis

Volumn 54, Issue 3, 2015, Pages 229-241

  Bana, Emilie ^a,b   Sibille, Estelle ^c   Valente, Sergio ^a   Cerella, Claudia ^b   Chaimbault, Patrick ^c   Kirsch, Gilbert ^a   Dicato, Mario ^b   Diederich, Marc ^d   Bagrel, Denyse ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b LABORATOIRE DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE DU CANCER   (Luxembourg)

^c UNIVERSITÉ DE LORRAINE   (France)

^d Seoul National University   (South Korea)

Author keywords

Apoptosis; Breast cancer; CDC25 inhibitor; Coumarin; Quinone; Reactive oxygen species

Indexed keywords

ANTINEOPLASTIC AGENT; BETA ACTIN; COUMARIN DERIVATIVE; CYCLIN DEPENDENT KINASE; NAPHTHOQUINONE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; SV 37; UNCLASSIFIED DRUG; 2-((7-METHOXY-2-OXO-2H-CHROMEN-4-YL)METHYLTHIO)NAPHTHALENE-1,4-DIONE; BENZOQUINONE; BENZOQUINONE DERIVATIVE; COUMARIN; ISOPROTEIN; SV 201 PROTEIN, SENDAI VIRUS; VIRUS PROTEIN;

ANALYTIC METHOD; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MCF 7 CELL LINE; PRIORITY JOURNAL; STRUCTURE ANALYSIS; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; FEMALE; METABOLISM; PATHOLOGY; SYNTHESIS; TUMOR CELL LINE;

APOPTOSIS; BENZOQUINONES; BREAST NEOPLASMS; CDC25 PHOSPHATASES; CELL LINE, TUMOR; CELL PROLIFERATION; COUMARINS; CYCLIN-DEPENDENT KINASES; DNA CLEAVAGE; FEMALE; HUMANS; MCF-7 CELLS; NAPHTHOQUINONES; PROTEIN ISOFORMS; REACTIVE OXYGEN SPECIES; VIRAL PROTEINS;

EID: 84926088320     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22094     Document Type: Article

References (53)

1. Russell P, Nurse P. cdc25+ functions as an inducer in the mitotic control of fission yeast. Cell 1986; 45:145-153.
2. Fauman EB, Saper MA. Structure and function of the protein tyrosine phosphatases. Trends Biochem Sci 1996; 21:413-417.
3. Ducommun B, Draetta G, Young P, Beach D. Fission yeast cdc25 is a cell-cycle regulated protein. Biochem Biophys Res Commun 1990; 167:301-309.
4. Rudolph J. Cdc25 phosphatases: Structure, specificity, and mechanism. Biochemistry 2007; 46:3595-3604.
5. Boutros R, Lobjois V, Ducommun B. CDC25B involvement in the centrosome duplication cycle and in microtubule nucleation. Cancer Res 2007; 67:11557-11564.
6. Hoffmann I, Karsenti E. The role of cdc25 in checkpoints and feedback controls in the eukaryotic cell cycle. J Cell Sci Suppl 1994; 18:75-79.
7. Jinno S, Suto K, Nagata A, et al. Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J 1994; 13:1549-1556.
8. Mizoguchi S, Kim KH. Expression of cdc25 phosphatases in the germ cells of the rat testis. Biol Reprod 1997; 56:1474-1481.
9. Gabrielli BG, Souza CP, De Tonks ID, Clark JM, Hayward NK, Ellem KA. Cytoplasmic accumulation of cdc25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells. J Cell Sci 1996; 109:1081-1093.
10. Izumi T, Maller JL. Phosphorylation and activation of the Xenopus Cdc25 phosphatase in the absence of Cdc2 and Cdk2 kinase activity. Mol Biol Cell 1995; 6:215-226.
11. Zwicker J, Lucibello FC, Wolfraim La, et al. Cell cycle regulation of the cyclin A, cdc25C, cdc2 genes is based on a common mechanism of transcriptional repression. EMBO J 1995; 14:4514-4522.
12. Boutros R, Dozier C, Ducommun B. The when and whereas of CDC25 phosphatases. Curr Opin Cell Biol 2006; 18:185-191.
13. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: Key players? Good targets? Nat Rev Cancer 2007; 7:495-507.
14. Cangi MG, Cukor B, Soung P, et al. Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest 2000; 106:753-761.
15. Bonin S, Brunetti D, Benedetti E, Gorji N, Stanta G. Expression of cyclin-dependent kinases and CDC25a phosphatase is related with recurrences and survival in women with peri- and post-menopausal breast cancer. Virchows Archiv 2006; 448:539-544.
16. Contour-Galcera MO, Sidhu A, Prevost G, Bigg D, Ducommun B. What's new on CDC25 phosphatase inhibitors. Pharmacol Ther 2007; 115:1-12.
17. Ferguson AM, White LS, Donovan PJ, Piwnica-Worms H. Normal cell cycle and checkpoint responses in mice and cells lacking Cdc25B and Cdc25C protein phosphatases. Mol Cell Biol 2005; 25:2853-2860.
18. Lincoln AJ, Wickramasinghe D, Stein P, et al. Cdc25b phosphatase is required for resumption of meiosis during oocyte maturation. Nat Genet 2002; 30:446-449.
19. Contour-Galcera MO, Lavergne O, Brezak MC, Ducommun B, Prevost G. Synthesis of small molecule CDC25 phosphatases inhibitors. Bioorg Med Chem Lett 2004; 14:5809-5812.
20. Ham SW, Park HJ, Lim DH. Studies on menadione as an inhibitor of the cdc25 phosphatase. Bioorg Chem 1997; 25:33-36.
21. Kar S, Lefterov IM, Wang M, et al. Binding and inhibition of Cdc25 phosphatases by vitamin K analogues. Biochemistry 2003; 42:10490-10497.
22. Sohn J, Kiburz B, Li Z, et al. Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones. J Med Chem 2003; 46:2580-2588.
23. Pu L, Amoscato AA, Bier ME, Lazo JS. Dual G1 and G2 phase inhibition by a novel, selective Cdc25 inhibitor 6-chloro-7-[corrected](2-morpholin-4-ylethylamino)-quinoline-5, 8-dione. J Biol Chem 2002; 277:46877-46885.
24. Cohen GM, d'Arcy Doherty M. Free radical mediated cell toxicity by redox cycling chemicals. Br J Cancer Suppl 1987; 8:46-52.
25. Monks TJ, Hanzlik RP, Cohen GM, Ross D, Graham DG. Quinone chemistry and toxicity. Toxicol Appl Pharmacol 1992; 112:2-16.
26. Brault L, Denancé M, Banaszak E, et al. Synthesis and biological evaluation of dialkylsubstituted maleic anhydrides as novel inhibitors of Cdc25 dual specificity phosphatases. Eur J Med Chem 2007; 42:243-247.
27. Viry E, Anwar A, Kirsch G, Jacob C, Diederich M, Bagrel D. Antiproliferative effect of natural tetrasulfides in human breast cancer cells is mediated through the inhibition of the cell division cycle 25 phosphatases. Int J Oncol 2011; 38:1103-1111.
28. Sibille E, Bana E, Chaouni W, Diederich M, Bagrel D, Chaimbault P. Development of a matrix-assisted laser desorption/ionization-mass spectrometry screening test to evidence reversible and irreversible inhibitors of CDC25 phosphatases. Anal Biochem 2012; 430:83-91.
29. da Silva D, Wasselin T, Carré V, et al. Evaluation of combined matrix-assisted laser desorption/ionization time-of-flight and matrix-assisted laser desorption/ionization Fourier transform ion cyclotron resonance mass spectrometry experiments for peptide mass fingerprinting analysis. Rapid Commun Mass Spectrom 2011; 25:1881-1892.
30. Cailleau R, Young R, Olive M, Reeves WJ Jr. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 1974; 53:661-674.
31. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973; 51:1409-1416.
32. Haegen BA, Van der Shay JW. Immortalization of human mammary epithelial cells by SV40 large T-antigen involves a two step mechanism. In Vitro Cell Dev Biol 1993; 29:180-182.
33. Gollahon LS, Shay JW. Immortalization of human mammary epithelial cells transfected with mutant p53 (273his). Oncogene 1996; 12:715-725.
34. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
35. Valente S, Bana E, Viry E, Bagrel D, Kirsch G. Synthesis and biological evaluation of novel coumarin-based inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett 2010; 20:5827-5830.
36. Brun MP, Braud E, Angotti D, et al. Design, synthesis, and biological evaluation of novel naphthoquinone derivatives with CDC25 phosphatase inhibitory activity. Bioorg Med Chem 2005; 13:4871-4879.
37. Brezak MC, Quaranta M, Contour-Galcera MO, et al. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases. Mol Cancer Ther 2005; 4:1378-1387.
38. Braud E, Goddard M-L, Kolb S, et al. Novel naphthoquinone and quinolinedione inhibitors of CDC25 phosphatase activity with antiproliferative properties. Bioorg Med Chem 2008; 16:9040-9049.
39. Brezak MC, Valette A, Quaranta M, et al. IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells. Int J Cancer 2009; 124:1449-1456.
40. Calba PJ, Muller JF, Hachimi A, et al. Spirooxazines as a molecular probe for the study of matrix-assisted laser desorption/ionization processes. Part I: Study of the interaction effect between the molecular probe and the matrix. Rapid Commun Mass Spectrom 1997; 11:1602-1611.
41. Lavecchia A, Giovanni C, Di Novellino E. CDC25 phosphatase inhibitors: An update. Mini Rev Med Chem 2012; 12:62-73.
42. Jänicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998; 273:9357-9360.
43. Blanc C, Deveraux QL, Krajewski S, et al. Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. Cancer Res 2000; 60:4386-4390.
44. Subik K, Baxter L, Strzepek T, et al. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer Basic Clin Res 2010; 4:35-41.
45. Papanikolaou V, Iliopoulos D, Dimou I, et al. The involvement of HER2 and p53 status in the regulation of telomerase in irradiated breast cancer cells. Int J Oncol 2009; 35:1141-1149.
46. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. J Am Med Assoc 2006; 295:1658-1667.
47. Sui M, Huang Y, Park BH, Davidson NE, Fan W. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res 2007; 67:5337-5344.
48. Brady-West DC, McGrowder DA. Triple negative breast cancer: Therapeutic and prognostic implications. Asian Pac J Cancer Prev 2011; 12:2139-2143.
49. Ying W, Wang S, Shi J, Sun Y. ER-/ER+ breast cancer cell lines exhibited different resistance to paclitaxel through pulse selection. Med Oncol 2012; 29:495-502.
50. Riaz M, Elstrodt F, Hollestelle A, Dehghan A, Klijn JG, Schutte M. Low-risk susceptibility alleles in 40 human breast cancer cell lines. BMC Cancer 2009; 9:236.
51. Brisson M, Foster C, Wipf P, et al. Independent mechanistic inhibition of cdc25 phosphatases by a natural product caulibugulone. Mol Pharmacol 2007; 71:184-192.
52. Rudolph J. Redox regulation of the Cdc25 phosphatases. Antioxid Redox Signal 2005; 7:761-767.
53. Buhrman G, Parker B, Sohn J, Rudolph J, Mattos C. Structural mechanism of oxidative regulation of the phosphatase Cdc25B via an intramolecular disulfide bond. Biochemistry 2005; 44:5307-5316.